RxDoctor Payments Data

Mandy Rath

Family · Steele, NDNPI 1386964138

Payments from drug & device makers

$525in general payments, 2019–2025

Across 25 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$102
  • AstraZeneca$97
  • Bayer$90
  • Boehringer Ingelheim$67
  • Astellas Pharma US Inc$62
  • Exact Sciences$35
  • plus $71 from 3 others

What the payments were for

  • Food & beverage$46388%
  • Education$6212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$525 in reported general payments places this provider in the 70th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$20,403
Medicare patients
67
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$70,548
JardianceEmpagliflozin59$47,251
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog53$19,882
XareltoRivaroxaban23$18,802
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,509
MyrbetriqMirabegron35$18,332
EliquisApixaban24$16,855
VraylarCariprazine Hcl12$16,812
Admelog SolostarInsulin Lispro16$7,444
FarxigaDapagliflozin Propanediol12$7,224
Breo ElliptaFluticasone/Vilanterol16$6,743
Spiriva RespimatTiotropium Bromide12$6,502
Fentanyl12$4,350
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc43$4,184
Oxycodone Hcl40$2,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$67$53,75371 claims
GSKTrelegy Ellipta, Breo Ellipta$31$25,25144 claims
Astellas Pharma US IncMyrbetriq$62$18,33235 claims
AstraZenecaFarxiga$97$7,22412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 496 family providers in North Dakota.

Other family in Steele

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →